April 7, 2006 -- The US Food and Drug Administration (FDA) has approved first-time generic formulations of glipizide 2.5-mg extended-release tablets for the management of type 2 diabetes; zidovudine ...

Glipizide/metformin HCl; 2.5mg/250mg, 2.5mg/500mg, 5mg/500mg; tabs. Adjunct to diet and exercise in type 2 diabetes, as initial therapy or as second-line therapy when response to a sulfonylurea or ...

Editor's Note: According to the FDA Web site, on Nov. 29, 2005, the FDA's Center for Drug Evaluation and Research (CDER) rescinded the Nov. 18, 2005, approval of Kali Laboratories' ANDA 76-506 for ...

Moderate-risk patients with diabetes treated with a sulfonylurea appear to be at a higher risk of major adverse cardiovascular events than those who receive a dipeptidyl peptidase-4 (DPP-4) inhibitor, ...

New research from investigators at Mass General Brigham suggests that a commonly used type 2 diabetes medication is linked to a higher rate of heart-related conditions compared to medications that hit ...

The diabetes drug glipizide was linked to a higher risk of serious heart problems compared to dipeptidyl peptidase-4, or DPP4, inhibitors in patients with Type 2 diabetes, according to a study ...

A comparative effectiveness research study compared MACE rates among initiators of sulfonylureas versus DPP4 inhibitors for T2D. Glipizide in particular showed a significant link to cardiovascular ...

The National Pharmaceutical Pricing Authority (NPPA) has brought down the prices of anti-diabetic bulk drug glipizide considerably, increased the prices of four other bulk drugs, and revised the ...

52-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar to Glipizide Plus Metformin in Improving Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus ...

STOCKHOLM--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced results from a randomized, double-blind Phase 3 clinical study in adults with type 2 ...